Cargando…

Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases

Studies have found that inflammation is a symptom of various diseases, such as coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA); it is also the source of other diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), lupus erythematosus (LE), and liver damage. Nrf2 (nuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Zhenzhen, Huang, Yanxin, Zhang, Yawei, Zhao, Lili, Li, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405369/
https://www.ncbi.nlm.nih.gov/pubmed/36009283
http://dx.doi.org/10.3390/antiox11081564
_version_ 1784773864028372992
author Zhai, Zhenzhen
Huang, Yanxin
Zhang, Yawei
Zhao, Lili
Li, Wen
author_facet Zhai, Zhenzhen
Huang, Yanxin
Zhang, Yawei
Zhao, Lili
Li, Wen
author_sort Zhai, Zhenzhen
collection PubMed
description Studies have found that inflammation is a symptom of various diseases, such as coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA); it is also the source of other diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), lupus erythematosus (LE), and liver damage. Nrf2 (nuclear factor erythroid 2-related factor 2) is an important multifunctional transcription factor in cells and plays a central regulatory role in cellular defense mechanisms. In recent years, several studies have found a strong association between the activation of Nrf2 and the fight against inflammation-related diseases. A number of small molecule compounds targeting Nrf2 have entered clinical research. This article reviews the research status of small molecule compounds that are in clinical trials for the treatment of COVID-19, rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, lupus erythematosus, and liver injury.
format Online
Article
Text
id pubmed-9405369
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94053692022-08-26 Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases Zhai, Zhenzhen Huang, Yanxin Zhang, Yawei Zhao, Lili Li, Wen Antioxidants (Basel) Review Studies have found that inflammation is a symptom of various diseases, such as coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA); it is also the source of other diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), lupus erythematosus (LE), and liver damage. Nrf2 (nuclear factor erythroid 2-related factor 2) is an important multifunctional transcription factor in cells and plays a central regulatory role in cellular defense mechanisms. In recent years, several studies have found a strong association between the activation of Nrf2 and the fight against inflammation-related diseases. A number of small molecule compounds targeting Nrf2 have entered clinical research. This article reviews the research status of small molecule compounds that are in clinical trials for the treatment of COVID-19, rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, lupus erythematosus, and liver injury. MDPI 2022-08-12 /pmc/articles/PMC9405369/ /pubmed/36009283 http://dx.doi.org/10.3390/antiox11081564 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhai, Zhenzhen
Huang, Yanxin
Zhang, Yawei
Zhao, Lili
Li, Wen
Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases
title Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases
title_full Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases
title_fullStr Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases
title_full_unstemmed Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases
title_short Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases
title_sort clinical research progress of small molecule compounds targeting nrf2 for treating inflammation-related diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405369/
https://www.ncbi.nlm.nih.gov/pubmed/36009283
http://dx.doi.org/10.3390/antiox11081564
work_keys_str_mv AT zhaizhenzhen clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases
AT huangyanxin clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases
AT zhangyawei clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases
AT zhaolili clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases
AT liwen clinicalresearchprogressofsmallmoleculecompoundstargetingnrf2fortreatinginflammationrelateddiseases